G2 checkpoint targeting via Wee1 inhibition radiosensitizes EGFRvIII-positive glioblastoma cells

[1]  C. Sørensen,et al.  WEE1 kinase protects the stability of stalled DNA replication forks by limiting CDK2 activity. , 2022, Cell reports.

[2]  U. Schüller,et al.  Increased replication stress and R-loop accumulation in EGFRvIII-expressing glioblastoma present new therapeutic opportunities , 2021, Neuro-oncology advances.

[3]  K. Rothkamm,et al.  Dual Inhibition of PARP and the Intra-S/G2 Cell Cycle Checkpoints Results in Highly Effective Radiosensitization of HPV-Positive HNSCC Cells , 2021, Frontiers in Oncology.

[4]  R. Syljuåsen,et al.  Expanding roles of cell cycle checkpoint inhibitors in radiation oncology , 2021, International journal of radiation biology.

[5]  Steven H. Lin,et al.  Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy , 2020, Clinical Cancer Research.

[6]  Zev A. Binder,et al.  EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma , 2020, Oncogene.

[7]  M. Schipper,et al.  Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  K. Kurian,et al.  Replication Stress Drives Constitutive Activation of the DNA Damage Response and Radioresistance in Glioblastoma Stem-like Cells. , 2018, Cancer research.

[9]  Jing Li,et al.  Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients , 2018, Clinical Cancer Research.

[10]  R. Verhaak,et al.  EGFR heterogeneity and implications for therapeutic intervention in glioblastoma , 2018, Neuro-oncology.

[11]  T. Lawrence,et al.  PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors , 2017, Molecular Cancer Research.

[12]  K. Rothkamm,et al.  G2-checkpoint targeting and radiosensitization of HPV/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  T. Lawrence,et al.  Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress. , 2016, International journal of radiation oncology, biology, physics.

[14]  T. Lawrence,et al.  Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair12 , 2015, Neoplasia.

[15]  T. Grob,et al.  EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells , 2015, Oncotarget.

[16]  T. Lawrence,et al.  Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer , 2014, Clinical Cancer Research.

[17]  Shawn M. Gillespie,et al.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma , 2014, Science.

[18]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2014, Cell.

[19]  G. Reifenberger,et al.  EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. , 2013, Cancer cell.

[20]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[21]  S. Patzke,et al.  Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption , 2012, Molecular and Cellular Biology.

[22]  R. Stupp,et al.  Neuro-oncology, a decade of temozolomide and beyond , 2010, Expert review of anticancer therapy.

[23]  J. Aten,et al.  In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. , 2010, Cancer cell.

[24]  A. Kaye,et al.  The EGFRvIII variant in glioblastoma multiforme , 2009, Journal of Clinical Neuroscience.

[25]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[26]  David J. Yang,et al.  Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients , 2005, Clinical Cancer Research.